West Pharmaceutical Services Inc. (WST) earns a Roarable Rating of A- (Buy) with 81/100 RQD Confidence. High-quality cash engine (36% profit margin, 18% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-02, West Pharmaceutical Services Inc. (NYSE: WST) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 81/100 at a spot price of $412.62 (-0.97% 1D, market cap $29.32B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, WST ranks #14 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), WST carries a Roarable A- (81/100 RQD), trailing P/E of 59.4x, gross margin of 35.9%, and ROIC of 17.9%. By comparison, DXCM (DexCom Inc.) holds a B+ grade (76/100 RQD, P/E 36.1x, ROIC 21.6%, cap $30.16B) and RMD (ResMed Inc.) posts a A grade (86/100 RQD, P/E 25.4x, ROIC 22.9%, cap $35.56B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).
Per WST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000105770), West Pharmaceutical Services Inc. generated $3.07B in revenue (+6.3% YoY), $493.7M in net income, and $468.9M in free cash flow against $4.27B in total assets and $202.8M in total debt. Key quantitative strengths: Strong cash generator (36% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 59x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 15.3% FCF Margin ($468.9M FCF) & 35.9% Gross Margin
20D Institutional Volume Accumulation (±5.3% realized swing band)
Disciplined Float (+0.24% YoY Shares) & executive Form 4 sales trim 9 pts from alignment
Even with a 81/100 (A-) score, WST faces multiple-compression risk if 59.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Priced at 59x earnings—high expectations leave less room for a lukewarm quarter.
Dilution & Margin Drag: Disciplined Float (+0.24% YoY Shares) — any gross margin slip below 33.4% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($370.14) or 200D SMA ($314.85) invalidates the momentum regime and cuts Target Base ($455.33) toward Bear Floor ($338.35).
West Pharmaceutical Services Inc. (WST) slipped -0.97% to $412.62, trading at 88% of its 52-week range ($223.83 – $438.27). High-quality cash engine (36% profit margin, 18% return on capital) with steady institutional support.
Yahoo Finance report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.
TradingView report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.
TradingView report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.
TradingView report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.
West Pharmaceutical Services reported past Q3 2026 results with sales of US$874.5 million and diluted EPS from continuing operations of US$3.02, and management raised full year 2026 net sales guidance to US$3.41 billion
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on WST today. View full Setup Ledger →
Across 1016 tracked Health Care securities in the Roarable RQD universe, West Pharmaceutical Services Inc. (WST) ranks #14 by composite RQD confidence (81/100, grade A-) and #59 by equity capitalization ($29.32B). Within this direct 5-issuer industry benchmark cohort, RMD leads on earnings valuation at 25.4x trailing P/E, while RMD leads on capital efficiency and profitability with 22.9% ROIC and 59.4% gross margin. RMD currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with WST at 81/100 (A-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| WST
ACTIVE
West Pharmaceutical Services Inc. | A- | 81/100 | 59.4x | 35.9% | 17.9% | -0.97% | $29.32B | Benchmark Subject |
| DXCM DexCom Inc. | B+ | 76/100 | 36.1x | 60.1% | 21.6% | +2.95% | $30.16B | /dxcm-vs-wst → |
| RMD ResMed Inc. | A | 86/100 | 25.4x | 59.4% | 22.9% | -9.05% | $35.56B | /rmd-vs-wst → |
| MDLN Medline Inc. | D | 44/100 | — | — | 8.2% | +0.38% | $42.07B | /mdln-vs-wst → |
| BDX Becton Dickinson and Company | C+ | 67/100 | 32.2x | 45.4% | 4.9% | -0.23% | $54.03B | /bdx-vs-wst → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), West Pharmaceutical Services Inc. (WST) reported GAAP revenue of $3.07B (+6.3% vs. FY2024 revenue of $2.89B , and +4.2% cumulative change since FY2023) , GAAP net income of $493.7M, operating cash flow of $754.8M, and free cash flow of $468.9M (+69.6% YoY). On the balance sheet, WST closed FY2025 with $4.27B in total assets against $202.8M in total debt (Altman Z-Score: 19.06, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.07B | $493.7M | $754.8M | $468.9M | $4.27B | $202.8M |
| FY2024 (FY) | 2024-12-31 | $2.89B | $492.7M | $653.4M | $276.4M | $3.64B | $202.6M |
| FY2023 (FY) | 2023-12-31 | $2.95B | $593.4M | $776.5M | $643.8M | $16.13B | $3.77B |
As of 2026-11-02, West Pharmaceutical Services Inc. (NYSE: WST) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 81/100 at a spot price of $412.62 (-0.97% 1D, market cap $29.32B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, WST ranks #14 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), WST carries a Roarable A- (81/100 RQD), trailing P/E of 59.4x, gross margin of 35.9%, and ROIC of 17.9%. By comparison, DXCM (DexCom Inc.) holds a B+ grade (76/100 RQD, P/E 36.1x, ROIC 21.6%, cap $30.16B) and RMD (ResMed Inc.) posts a A grade (86/100 RQD, P/E 25.4x, ROIC 22.9%, cap $35.56B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).
Per WST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000105770), West Pharmaceutical Services Inc. generated $3.07B in revenue (+6.3% YoY), $493.7M in net income, and $468.9M in free cash flow against $4.27B in total assets and $202.8M in total debt. Key quantitative strengths: Strong cash generator (36% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 59x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
WST last traded at $412.62 (-0.97% on volume of 1,062,356 shares), positioning the stock +11.48% above its 50-day simple moving average ($370.14) and +31.05% above its 200-day simple moving average ($314.85). Across its 52-week range of $223.83 to $438.27, WST sits at the 88.0% percentile with a 14-day RSI of 77.0 (OVERBOUGHT (>70)) and an implied next-earnings move of ±5.3% ($390.75 to $434.49).
Why WST Stock slipped -0.97% Today — RQD Quant Desk Flash. High-quality cash engine (36% profit margin, 18% return on capital) with steady institutional support.
Per the Roarable RQD rating, WST scores 81 out of 100, earning a letter grade of A- and the verdict label "Roarable Buy — Superior Risk/Reward." The score is built from five pillars:
For a prospective investor, the investment case rests on high-quality returns and a clean balance sheet, offset by a demanding valuation (P/E TTM 59.4, EV/EBITDA 34.7) and weaker insider conviction. The RQD score describes the relative quality of the setup as rated; it does not establish that the stock will outperform.
Per the profile, West Pharmaceutical Services Inc. is a NYSE-listed issuer in the Health Care sector, Medical/Dental Instruments industry. Per the Butterfly Supply-Chain Graph, the company manufactures NovaPure fluoropolymer-coated elastomer plungers and cartridge seals used inside sterile GLP-1 auto-injector pens, positioning it as a component supplier to biopharma drug delivery. Not available in source data for customer concentration, segment revenue split, or detailed revenue model.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $3074.1M | $584.9M | $493.7M | N/A | $468.9M | $791.3M | $202.8M |
| FY 2024 | $2893.2M | $569.9M | $492.7M | N/A | $276.4M | $484.6M | $202.6M |
| FY 2023 | $2949.8M | $676.0M | $593.4M | N/A | $643.8M | N/A | $3773.9M |
Per the market data, gross margin is 35.9%, operating margin 19%, and net margin 16.1%. Per the RQD rating, ROIC is 17.9%, Altman Z-Score 19.06, and Piotroski F-Score 9/9. Debt/Equity is 0.06 per the RQD rating. Reported revenue rose from $2949.8M (FY 2023) to $3074.1M (FY 2025), while FY 2023 debt of $3773.9M contrasts with $202.8M in FY 2025, a shift the source data does not explain.
Real-time company headlines, analyst actions, and sector developments for West Pharmaceutical Services Inc. (WST) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.
TradingView report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.
TradingView report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.
TradingView report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering West Pharmaceutical Services Inc. (WST) market action, institutional positioning, and fundamental catalysts.
Welcome to the WST (West Pharmaceutical Services Inc.) Roar Pit. Current RQD Composite is 81/100 (Roarable Buy — Superior Risk/Reward) in Medical/Dental Instruments. Bulls point to capital efficiency (17.9% ROIC), while bears focus on valuation multiple compression (59.4x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on WST, but look at what you are paying: 59.4x trailing P/E with 35.9% gross margins. Unless West Pharmaceutical Services Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on WST, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $416.67 (52-wk range $223.83 - $438.27), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).